# US 8,277,835 B2 · Nutritional composition comprising immunoglobulins and oligosaccharides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,835 B2
- Document ID: US8277835B2
- Status: Granted
- Kind: B2
- Application number: 11/574,123
- Filed: 2005-08-24
- Published: 2007-11-29
- Granted: 2012-10-02
- Earliest claimed: 2004-08-24
- Assignees: N. V. Nutricia
- Inventors: Günther Boehm; Laura M'Rabet; Bernd Stahl; Johan Garssen; Antony William Scammell; Raymonde Peter Peeters
- Web page: https://patentgrep.com/patent/US8277835B2

## CPC

- A61K 31/702: Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
- A23L 33/12: Fatty acids or derivatives thereof
- A23L 33/21: Addition of substantially indigestible substances, e.g. dietary fibres
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/733: Fructosans, e.g. inulin
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 39/42: viral
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/18: for HIV
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2400/519: Breve
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention provides a method and composition for the treatment and/or prevention of infection, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and immunoglobulin from the milk or colostrum of hyperimmunized cows.

## Claims

### Claim 1

A method of reducing the incidence of upper respiratory tract infection episodes comprising administering to an infant mammal in need thereof a liquid infant formula composition consisting of:
(a) 0.5-10 grams transgalactooligosaccharide per 100 grams dry weight of the composition,
(b) 0.5-10 grams fructopolysaccharide per 100 grams dry weight of the composition,
(c) optionally, indigestible dextrins, xylooligosaccharides, arabinooligosaccharides, glucooligosaccharides, mannooligosaccharides, fucooligosaccharides, fructans, fructooligosaccharide, hydrolysed inulin, inulin or lactose, and
(d) optionally, a long chain polyunsaturated fatty acid (LC-PUFA),
wherein, as a percentage of the total caloric value of the composition, (i) 35-50% energy is derived from fat; (ii) 7.5-12.5% energy is derived from protein; and 40-55% energy is derived from carbohydrate; and
wherein the composition is in the form of a liquid and does not comprise human milk.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the mammal is a human.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the composition is administered orally.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the fat, carbohydrate, or protein is of plant, non-human animal, bacterial, or synthetic origin.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the composition consists of
(a) 2-5 grams transgalactooligosaccharide per 100 grams dry weight of the composition, and
(b) 1-5 grams fructopolysaccharide per 100 grams dry weight of the composition,
wherein the composition is in the form of a liquid and does not comprise human milk.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the composition consists of:
(a) 0.5-10 grams transgalactooligosaccharide per 100 grams dry weight of the composition,
(b) 0.5-10 grams fructopolysaccharide per 100 grams dry weight of the composition,
(c) a fructan, fructooligosaccharide, a hydrolysed inulin or an inulin, and
(d) optionally, a long chain polyunsaturated fatty acid (LC-PUFA),
wherein, as a percentage of the total caloric value of the composition, (i) 35-50% energy is derived from fat; (ii) 7.5-12.5% energy is derived from protein; and 40-55% energy is derived from carbohydrate; and
wherein the composition is in the form of a liquid and does not comprise human milk.

### Claim 7 (depends on 1)

The method according to claim 1, wherein at least 50%, by weight, of the carbohydrate of the composition is lactose.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the LC-PUFA is selected from the group consisting of eicosapentaenoic acid (EPA, n-3), docosahexaenoic acid (DHA, n-3) and arachidonic acid (AA, n-6).

### Claim 9

A method of reducing the incidence of upper respiratory tract infection episodes comprising administering to an infant mammal in need thereof a liquid infant formula composition consisting of:
(a) 0.5-10 grams transgalactooligosaccharide per 100 grams dry weight of the composition,
(b) 0.5-10 grams fructopolysaccharide per 100 grams dry weight of the composition,
(c) optionally, indigestible dextrins, xylooligosaccharides, arabinooligosaccharides, glucooligosaccharides, mannooligosaccharides, fucooligosaccharides, fructans, fructooligosaccharide, hydrolysed inulin or inulin, and
(d) optionally, a long chain polyunsaturated fatty acid (LC-PUFA),
wherein the composition is in the form of a liquid and does not comprise human milk.
